About Alzinova
Alzinova AB is a Swedish biotechnology enterprise engaged in drug discovery research for Alzheimer’s disease. The company's proprietary AβCC peptide™ technology provides the company with long-term R&D capabilities. This technology enables Alzinova to explore novel therapeutic strategies and develop research tools that enhance productivity within Alzheimer's disease research.
Read more »Research
Non-fibrillogenic mimics of endogenous toxic amyloid-β aggregates ('oligomers') are developed by Alzinova as vaccines with high efficacy. The unique properties of the AβCC peptide™ technology has also enabled the development of a monoclonal antibody with 100% specificity for the synapse-damaging oligomers. It is currently under validation as a diagnostic tool.
News
-
Alzinova uppdaterar statusläget för bolaget
Per Wester, VD i Alzinova, önskar härmed uppdatera aktieägarna om de prekliniska projekt som pågår… Read more »
-
Alzinova inleder EU finansierat SME instruments steg 1 projekt och tilldelas coach
Alzinova har nu påbörjat projektet ”Novel Immunotherapeutic Vaccine for the treatment of Alzheimer’s disease (IMMOVA)”,… Read more »
-
Alzinovas styrelsemedlem Prof. Jan Holmgren tilldelas ”vaccinforskningens eget Nobelpris”
Professor Jan Holmgren har tilldelats Sabin Gold Medal, som brukar kallas vaccinforskningens eget nobelpris. Priset… Read more »